Atricure Inc (ATRC) 15.50 $ATRC
AtriCure to Present at the Morgan Stanley Global Healthcare Conference
BusinessWire - Thu Aug 18, 3:01PM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt Hotel in New York City on Wednesday, September 14, 2016. Management is scheduled to present at 11:05 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure's corporate website at www.atricure.com. A replay of the presentation will be available for 90 days following the presentation.
ATRC: 15.50 (+0.11), MS: 31.91 (-0.15)
AtriCure Reports Second Quarter 2016 Financial Results
BusinessWire - Thu Aug 04, 3:01PM CDT
--U.S. sales of $30.9 million - up 19.9%
ATRC: 15.50 (+0.11)
Medical Product Stock Earnings on Aug 4: NXTM, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:56AM CDT
Here, we take a look at four Medical product stocks set to report their quarterly figures on Aug 4.
NXTM: 22.86 (unch), AGIO: 36.74 (-0.10), ATRC: 15.50 (+0.11), HRC: 59.25 (-0.06)
AtriCure Announces the First Patient Enrolled in the FROST Cryoanalgesia Study
BusinessWire - Tue Jun 21, 7:00AM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced the first patient has been enrolled in the FROST study at William Beaumont Hospital, Dearborn, MI. This company-sponsored trial will evaluate intraoperative cryoanalgesia therapy using cryoablation in conjunction with standard of care (SOC) pain management compared to SOC alone.
ATRC: 15.50 (+0.11)
AtriCure to Present at the UBS Global Healthcare Conference
BusinessWire - Mon May 02, 3:01PM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the UBS Global Healthcare Conference at the Grand Hyatt in New York on Monday, May 23, 2016. Management is scheduled to present at 11:00 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure's corporate website at www.atricure.com. A replay of the presentation will be available for 90 days following the presentation.
ATRC: 15.50 (+0.11)
AtriCure Reports First Quarter 2016 Financial Results
BusinessWire - Thu Apr 28, 3:05PM CDT
--U.S. sales of $28.3 million - up 23.3%
ATRC: 15.50 (+0.11)
AtriCure Announces $25 Million Term Loan with Silicon Valley Bank
BusinessWire - Thu Apr 28, 3:01PM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has entered into an amended and restated term loan and revolving line of credit agreement with Silicon Valley Bank, providing access to a new $25 million five-year term loan, as well as renewing a $15 million revolving line of credit.
ATRC: 15.50 (+0.11)
AtriCure Receives FDA Clearance for New AtriClip(R) Device
BusinessWire - Tue Apr 26, 7:00AM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the AtriClip PRO2 Left Atrial Appendage (LAA) Exclusion System. The new AtriClip PRO2 system has increased functionality which enhances the capability to occlude the LAA during minimally-invasive surgical (MIS) procedures.
ATRC: 15.50 (+0.11)
New Strong Buy Stocks for April 19th
Zacks Equity Research - Zacks Investment Research - Tue Apr 19, 8:33AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
BMA: 78.46 (+0.12), BV: 4.05 (+0.05), ANCX: 22.35 (+0.07), MTGE: 17.01 (-0.05), ATRC: 15.50 (+0.11)
What Falling Estimates & Price Mean for INSYS Therapeutics (INSY)
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 4:59PM CDT
INSYS Therapeutics has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off.
INSY: 14.36 (+0.09), ATRC: 15.50 (+0.11)
AtriCure Announces 510(k) Clearance for the cryoFORM(TM) Cryoablation Probe
BusinessWire - Tue Apr 12, 7:00AM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has received 510(k) clearance for the cryoFORM cryoablation probe, which offers increased probe flexibility to adapt to a variety of surgical ablation procedures. The probe was previously launched in October 2015 in the European market under a CE mark.
ATRC: 15.50 (+0.11)
AtriCure to Announce First Quarter 2016 Financial Results
BusinessWire - Tue Apr 05, 3:01PM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the first quarter of 2016 on Thursday, April 28, 2016.
ATRC: 15.50 (+0.11)
New Strong Buy Stocks for March 29th
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 8:06AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
BPMC: 27.62 (-0.26), BXE: 0.76 (-0.04), BKCC: 8.69 (-0.03), AKAO: 3.99 (+0.22), ATRC: 15.50 (+0.11)
AtriCure Down 19.0% Since SmarTrend Downtrend Call (ATRC)
Comtex SmarTrend(R) - Tue Feb 09, 10:17AM CST
SmarTrend identified a Downtrend for AtriCure (NASDAQ:ATRC) on January 8th, 2016 at $20.08. In approximately 1 month, AtriCure has returned 19.00% as of today's recent price of $16.26.
ATRC: 15.50 (+0.11)
AtriCure to Announce Fourth Quarter and Full Year 2015 Financial Results
BusinessWire - Mon Feb 01, 3:00PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the fourth quarter and full year 2015 on Tuesday, February 23, 2016.
ATRC: 15.50 (+0.11)
Downtrend Call Working As AtriCure Stock Falls 16.6% (ATRC)
Comtex SmarTrend(R) - Fri Jan 29, 10:48AM CST
SmarTrend identified a Downtrend for AtriCure (NASDAQ:ATRC) on January 8th, 2016 at $20.08. In approximately 3 weeks, AtriCure has returned 16.56% as of today's recent price of $16.75.
ATRC: 15.50 (+0.11)
AtriCure to Present at the Leerink Global Healthcare Conference
BusinessWire - Thu Jan 21, 7:00AM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Leerink Global Healthcare Conference at the Waldorf Astoria Hotel in New York on Thursday, February 11, 2016. Management is scheduled to present at 8:05 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure's corporate website at www.atricure.com. A replay of the presentation will be available for 90 days following the presentation.
ATRC: 15.50 (+0.11)
AtriCure to Present at the Morgan Stanley Global Healthcare Conference
BusinessWire - Thu Aug 18, 3:01PM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt Hotel in New York City on Wednesday, September 14, 2016. Management is scheduled to present at 11:05 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure's corporate website at www.atricure.com. A replay of the presentation will be available for 90 days following the presentation.
ATRC: 15.50 (+0.11), MS: 31.91 (-0.15)
AtriCure Reports Second Quarter 2016 Financial Results
BusinessWire - Thu Aug 04, 3:01PM CDT
--U.S. sales of $30.9 million - up 19.9%
ATRC: 15.50 (+0.11)
Medical Product Stock Earnings on Aug 4: NXTM, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:56AM CDT
Here, we take a look at four Medical product stocks set to report their quarterly figures on Aug 4.
NXTM: 22.86 (unch), AGIO: 36.74 (-0.10), ATRC: 15.50 (+0.11), HRC: 59.25 (-0.06)
AtriCure Announces the First Patient Enrolled in the FROST Cryoanalgesia Study
BusinessWire - Tue Jun 21, 7:00AM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced the first patient has been enrolled in the FROST study at William Beaumont Hospital, Dearborn, MI. This company-sponsored trial will evaluate intraoperative cryoanalgesia therapy using cryoablation in conjunction with standard of care (SOC) pain management compared to SOC alone.
ATRC: 15.50 (+0.11)
AtriCure to Present at the UBS Global Healthcare Conference
BusinessWire - Mon May 02, 3:01PM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the UBS Global Healthcare Conference at the Grand Hyatt in New York on Monday, May 23, 2016. Management is scheduled to present at 11:00 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure's corporate website at www.atricure.com. A replay of the presentation will be available for 90 days following the presentation.
ATRC: 15.50 (+0.11)
AtriCure Reports First Quarter 2016 Financial Results
BusinessWire - Thu Apr 28, 3:05PM CDT
--U.S. sales of $28.3 million - up 23.3%
ATRC: 15.50 (+0.11)
AtriCure Announces $25 Million Term Loan with Silicon Valley Bank
BusinessWire - Thu Apr 28, 3:01PM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has entered into an amended and restated term loan and revolving line of credit agreement with Silicon Valley Bank, providing access to a new $25 million five-year term loan, as well as renewing a $15 million revolving line of credit.
ATRC: 15.50 (+0.11)
AtriCure Receives FDA Clearance for New AtriClip(R) Device
BusinessWire - Tue Apr 26, 7:00AM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the AtriClip PRO2 Left Atrial Appendage (LAA) Exclusion System. The new AtriClip PRO2 system has increased functionality which enhances the capability to occlude the LAA during minimally-invasive surgical (MIS) procedures.
ATRC: 15.50 (+0.11)
New Strong Buy Stocks for April 19th
Zacks Equity Research - Zacks Investment Research - Tue Apr 19, 8:33AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
BMA: 78.46 (+0.12), BV: 4.05 (+0.05), ANCX: 22.35 (+0.07), MTGE: 17.01 (-0.05), ATRC: 15.50 (+0.11)
What Falling Estimates & Price Mean for INSYS Therapeutics (INSY)
Zacks Equity Research - Zacks Investment Research - Fri Apr 15, 4:59PM CDT
INSYS Therapeutics has witnessed a significant price decline in the past four weeks and negative estimate revisions, making it time for investors to sell it off.
INSY: 14.36 (+0.09), ATRC: 15.50 (+0.11)
AtriCure Announces 510(k) Clearance for the cryoFORM(TM) Cryoablation Probe
BusinessWire - Tue Apr 12, 7:00AM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has received 510(k) clearance for the cryoFORM cryoablation probe, which offers increased probe flexibility to adapt to a variety of surgical ablation procedures. The probe was previously launched in October 2015 in the European market under a CE mark.
ATRC: 15.50 (+0.11)
AtriCure to Announce First Quarter 2016 Financial Results
BusinessWire - Tue Apr 05, 3:01PM CDT
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the first quarter of 2016 on Thursday, April 28, 2016.
ATRC: 15.50 (+0.11)
New Strong Buy Stocks for March 29th
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 8:06AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
BPMC: 27.62 (-0.26), BXE: 0.76 (-0.04), BKCC: 8.69 (-0.03), AKAO: 3.99 (+0.22), ATRC: 15.50 (+0.11)
AtriCure Down 19.0% Since SmarTrend Downtrend Call (ATRC)
Comtex SmarTrend(R) - Tue Feb 09, 10:17AM CST
SmarTrend identified a Downtrend for AtriCure (NASDAQ:ATRC) on January 8th, 2016 at $20.08. In approximately 1 month, AtriCure has returned 19.00% as of today's recent price of $16.26.
ATRC: 15.50 (+0.11)
AtriCure to Announce Fourth Quarter and Full Year 2015 Financial Results
BusinessWire - Mon Feb 01, 3:00PM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, will release its financial results for the fourth quarter and full year 2015 on Tuesday, February 23, 2016.
ATRC: 15.50 (+0.11)
Downtrend Call Working As AtriCure Stock Falls 16.6% (ATRC)
Comtex SmarTrend(R) - Fri Jan 29, 10:48AM CST
SmarTrend identified a Downtrend for AtriCure (NASDAQ:ATRC) on January 8th, 2016 at $20.08. In approximately 3 weeks, AtriCure has returned 16.56% as of today's recent price of $16.75.
ATRC: 15.50 (+0.11)
AtriCure to Present at the Leerink Global Healthcare Conference
BusinessWire - Thu Jan 21, 7:00AM CST
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Leerink Global Healthcare Conference at the Waldorf Astoria Hotel in New York on Thursday, February 11, 2016. Management is scheduled to present at 8:05 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure's corporate website at www.atricure.com. A replay of the presentation will be available for 90 days following the presentation.
ATRC: 15.50 (+0.11)
